JSC Olainfarm and Adalvo have signed a licensing and supply agreement to launch a new product in the urology segment which is targeted to be the 1st to market opportunity in all of these markets. The prescription product will help millions of patients in 17 different countries to regain ease and quality of life. In partnership Olainfarm will manage product regulatory affairs, distribution and promotion in Latvia, Russia, Kazakhstan, Belarus, Ukraine, and other countries of current presence and Adalvo will be responsible for development, manufacturing and will support Olainfarm for its market access activities in all the markets. Currently, Olainfarm has established a sustainable business model in the EU and CIS countries with more than 300 medical and marketing professionals. Full commercialization of this prescription product is expected to be in 2022-2023.